Tekmira Announces New Preclinical Data from Anti-Viral Programs
November 12, 2013 17:00 ET
|
Arbutus Biopharma Corporation
Results Demonstrate Survival Following Lethal Infection When Treatment Is Delayed
VANCOUVER, British Columbia, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR)...
Tekmira's Partner Initiates Phase III Trial With LNP-Enabled Patisiran (ALN-TTR02)
November 10, 2013 23:28 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 10, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Conference Call and Webcast Advisory: Corporate Update and Third Quarter Financial Results
November 07, 2013 17:04 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Announces Closing of Underwriters' Full Over-Allotment Option
November 01, 2013 11:12 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 1, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Preclinical Data Presented at Scientific Symposium Demonstrates That mRNA is Efficiently Delivered Using Tekmira's LNP
October 24, 2013 08:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Announces Completion of US$30 Million Public Offering of Common Stock
October 22, 2013 10:16 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Prices Public Offering of Common Stock
October 17, 2013 08:48 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 17, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Announces Proposed Public Offering of Common Stock
October 16, 2013 16:01 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Provides Corporate Update on RNAi Therapeutics Pipeline
October 08, 2013 16:00 ET
|
Arbutus Biopharma Corporation
Tekmira Builds Upon Extensive Experience in Anti-Viral Therapeutics by Adding Therapeutics Addressing Hepatitis B and Marburg Virus to Product Pipeline
TKM-ALDH2, an RNAi Therapeutic for Alcohol...
Tekmira Appoints Bruce Cousins as Executive Vice President and Chief Financial Officer
October 07, 2013 16:00 ET
|
Arbutus Biopharma Corporation
VANCOUVER, B.C., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that Mr....